Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.

Sands, Bruce E; Schreiber, Stefan; Blumenstein, Irina; Chiorean, Michael V; Ungaro, Ryan C; Rubin, David T

Sands, Bruce E; Schreiber, Stefan; Blumenstein, Irina; Chiorean, Michael V; Ungaro, Ryan C; Rubin, David T.

Affiliation

Sands BE; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Schreiber S; Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
Blumenstein I; Medical Clinic 1, Department of Gastroenterology, Hepatology and Clinical Nutrition, Goethe University Hospital, Frankfurt, Germany.
Chiorean MV; Department of Gastroenterology, Swedish Medical Center, Seattle, WA, USA.
Ungaro RC; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rubin DT; Section of Gastroenterology, Hepatology & Nutrition, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.

J Crohns Colitis ; 17(12): 2012-2025, 2023 Dec 30.

Article de En | MEDLINE | ID: mdl-37436357

Sujet(s)
Mots clés

S1P receptor modulator; Ulcerative colitis; ozanimod

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Rectocolite hémorragique Type d'étude: Guideline / Risk_factors_studies Limites: Adult / Humans Langue: En Journal: J Crohns Colitis Sujet du journal: GASTROENTEROLOGIA Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google